Influenza vaccination was carried out with the trivalent component vaccine (Afluria, Seqirus USA Inc., King of Prussia, PA) or for patients’ ages 65 years and older (Fluzone, Sanofi Pasteur, Swiftwater, PA). Both of these vaccines were administered in a single dose of 0.5 mL intramuscularly.
Vaccination for pneumococcal pneumonia was carried out with either the PPSV23 (Pneumovax, Merck, Whitehouse Station, NJ) or with the PCV13 (Prevnar 13, Pfizer, Philadelphia, PA). Both vaccines were administered in a single dose of 0.5 mL intramuscularly. The selection of which pneumococcal vaccine was appropriate for the patient to receive was based on ACIP guidelines for these two vaccines.
Vaccination for hepatitis B was carried out with the Energix-B (Glaxo Smith Kline, Research Triangle Park, NC), administered in a three-dose series with 1.0 mL given at 0, 1, and 6 months or for patients receiving a booster, a single intramuscular dose of 1.0 mL was given.
Serum was obtained at the baseline visit prior to vaccination, and subjects returned 2–4 weeks later for follow-up blood collection. At this follow-up visit, subjects again completed the HBI for CD or SCCAI for UC questionnaire and were assessed for adverse events. Patients received a follow-up phone call between the initiation and follow-up visit to assess for adverse events.
Vaccination for pneumococcal pneumonia was carried out with either the PPSV23 (Pneumovax, Merck, Whitehouse Station, NJ) or with the PCV13 (Prevnar 13, Pfizer, Philadelphia, PA). Both vaccines were administered in a single dose of 0.5 mL intramuscularly. The selection of which pneumococcal vaccine was appropriate for the patient to receive was based on ACIP guidelines for these two vaccines.
Vaccination for hepatitis B was carried out with the Energix-B (Glaxo Smith Kline, Research Triangle Park, NC), administered in a three-dose series with 1.0 mL given at 0, 1, and 6 months or for patients receiving a booster, a single intramuscular dose of 1.0 mL was given.
Serum was obtained at the baseline visit prior to vaccination, and subjects returned 2–4 weeks later for follow-up blood collection. At this follow-up visit, subjects again completed the HBI for CD or SCCAI for UC questionnaire and were assessed for adverse events. Patients received a follow-up phone call between the initiation and follow-up visit to assess for adverse events.